inhibitors in Norway. Pharmacoeconomic analyses also show that large financial resources would be saved if the structure of the utilized ACE inhibitors in Serbia were more similar to the one in Norway.

PCV17

A CROSS-SECTIONAL ASSESSMENT OF ATRIAL FIBRILLATION MANAGEMENT AMONG FRENCH PATIENTS IN PRIMARY CARE

Sabouret P1, Willems C2, Cotte FF3, Marie P4, Mercier F4, Depret-Bixio L5, Blin P5, 1Hospital-Privee Hopitaux, Rueil-Malmaison, France, 2Bristol-Myers Squibb, Rueil-Malmaison, France, 3Bristol-Myers Squibb, Rueil-Malmaison, France, 4SaintProcess, Port-Mort, France, 5Bordeaux University, Bordeaux, France

OBJECTIVES: Around 80,000 patients are diagnosed for atrial fibrillation (AF) in France with an increased risk of strokes. For many of them, prevention with anti-coagulant is managed in primary care. Prevention should be driven by individual risk for stroke estimated with a score (CHADS2) ranging from 0 (lower risk) to 6 (higher risk). This study was to describe AF patients’ management by general practice and to assess the accuracy of individual risk assessment in the French primary care.

The study analyzed a medical files and prescriptions database of a representative sample of 1,200 GPs. Data from all patients present in the database from July-2010 to June-2011, with a diagnosis of AF and aged 18 and above were extracted. Based on age (>75), comorbidities (HITA/ Diabetes) and history of stroke/TIA/CHF, CHADS2 was calculated for all patients. Under-treatment status was defined according European guidelines which recommend prevention with aspirin or vitamin-K antagonists (VKA) for CHADS2=1 and VKA for CHADS2=2. RESULTS: A total of 15,623 AF patients were identified. Mean age was 74.6±11 years old, 59.9% were men and mean CHADS2 was 1.5±1.3. 12,985 patients (83.1%) were found eligible for stroke prevention (i.e.CHADS2=1). Among them, 23.4% received no prevention at all, 11.4% were under-treated (i.e. aspirin instead of VKA) and 4.7% received non-recommended treatment (i.e. clopidogrel). Within patients with CHADS2=1 (n=5,026), 26.7% had no treatment, 48.9%, 20.5% and 5.0% were treated with VKA, aspirin and clopidogrel, respectively. Within those with CHADS2=2 (n=7,959), only 54.9% received VKA when 21.3% had no treatment and 18.6% and 5.1% were prescribed aspirin and clopidogrel respectively. CONCLUSIONS: In this large study in French primary care, four out of five (80%) of patients diagnosed with AF should benefit from stroke prevention. Overall, around 45% of thromboembolic high-risk patients (i.e.CHADS2=2) were not treated or inadequately treated. Future analyses should be performed to investigate the gap between clinical practice and guidelines.

PCV18

CARDIOVASCULAR RISK ASSESSMENT USING FRAMINGHAM RISK EQUATION IN NEUALLY DIAGNOSED TYPE 2 DIABETIC INDIAN PATIENTS

Sujata C1, Tiwari P2, Bhansali A3
1National Institute of Pharmaceutical Education and Research (NIPER), S A S Nagar, Punjab, India, 2National Institute of Pharmaceutical Education and Research (NIPER), S A S Nagar, Punjab, India, 3Post Graduate Institute of Medical Education and Research, Chandigarh, India

OBJECTIVES: The risk of cardiovascular disease (CVD) is reported to be 2-4 times more similar to the one in Norway.

This was a prospective, observational, questionnaire based study conducted in a tertiary care hospital. The risk of cardiovascular disease (CVD) is reported to be 2-4 times higher in patients with type 2 diabetes mellitus (T2DM). CVD is the major cause of morbidity and mortality for diabetics and contributes most to the costs of diabetes. To estimate the effectiveness of using a simple risk score comprising risk factors in CVD in newly diagnosed T2DM patients.

METHODS: This was a prospective, observational, questionnaire based study conducted in a tertiary care hospital. Only patients with newly diagnosed diabetes ≥ 6 months were recruited. Risk factors related to CVD in these patients were identified and the 10 year cardiovascular risk was estimated using Framingham risk equation. RESULTS: The results are based on a total of 152 newly diagnosed T2DM patients. The major modifiable risk factors were identified as obesity (59%), hypertension (56%), dyslipidemia (54%), smoking (47%) and diabetes (24%). The prevalence of various microvascular and macrovascular complications at the time of diagnosis was also assessed; 26% patients were found to have neuropathy followed by nephropathy in 7%. Only 5% patients were diagnosed with coronary artery disease (CAD) along with T2DM. The 10 year CVD risk estimation showed that the females were at higher risk compared to males (10 vs 6%). Further, the association of the cardiovascular risk with the risk factors was analysed using linear regression logistic. The risk was found to be significantly associated with age (>55 vs ≤ 55 years) with an odds ratio of 3.38 (95% CI 1.14-10.02, P=0.03). CONCLUSIONS: The prevalence of risk factors for CVD in newly diagnosed T2DM patients was found to be high; however, the estimated risk was low according to the Framingham risk scoring system. Therefore, the authors suggest that timely management of these risk factors is needed to reduce the occurrence of CVD.

PCV20

BUDGET IMPACT OF INTERNAL REFERENCE PRICING FOR STATINS IN TURKEY

Kockaya C1, Tuna E2, Atikeler K3
1Health Economics and Policy Association, Ankara, Turkey, 2Hacettepe University, Ankara, Turkey, 3Ankara University, Ankara, Turkey

OBJECTIVES: Turkey pharmaceutical market is a growing market in spite of government policies. Public pharmaceutical market rise from 7.9 billion TL to 15.5 billion TL from 2000 to 2009. In addition, Cardiovascular system medicines market rise from 18% to 21% from 2005 to 2009. Statins market was 21% of the cardiovascular system medicines expenditures. Statins have the same effectiveness and safety profile. So each statin may use instead of others. Internal reference pricing may use for statins in Turkey. The aim of the study was to simulate possible budget impact of jumbo basket application for statins in Turkey. METHODS: Statins consumption for year 2010 was taken from IMS. Possible 4 different budget scenarios were calculated. Scenario A defined as reimburse all statins with the minimum statin price. Scenario B defined as reimburse all statins with 15% of minimum statin price. Scenario C or D may be acceptable for the industry and offer government 37% or 35% extra decrease in statin expenditure. This pilot study may spotlight possible opportunities in the controlling statin market budget for government.

PCV21

BUDGET IMPACT ANALYSIS OF INTRODUCING OF PCMV-VEGF165 FOR TREATMENT OF CRITICAL LIMB ISCHEMIA FROM THE RUSSIAN HEALTH CARE SYSTEM PERSPECTIVE

Yagudina R1, Kulikov A2, Kogon L3
1First Moscow State Medical University named after I. M. Sechenov, Moscow, Russia, 2First Moscow State Medical University named after I. M. Sechenov, Moscow, Moscow, Russia, 3VGBR, NCESMP Minzdravsocrazvitiya RF, Moscow, Russia, Moscow, Russia

OBJECTIVES: Plasmid pCMV-VEGF165 is new injectable factor, activating therapeutic angiogenesis in the ischemic limb and facilitating reduction of amputation rate. It was developed for ischemic limb in patients who cannot undergo reconstructive arterial surgery. pCMV-VEGF165 was recently approved for use in Russia and not yet included in government reimbursement list, therefore suitable patients with CLI do not have general access to it. A budget impact analysis would provide evidence to assist budget holders in decision making processes. METHODS: A budget impact model was built to allow assessment of the budgetary impact to the Federal state budget from health care system perspective if pCMV-VEGF165 is introduced into state reimbursement system in 2-year time horizon. The scenarios adopted were world (standard treatment of CLI) with and without pCMV-VEGF165. A cohort of 26 812 patients with unreconstructable CLI was used as population according to epidemiology data in Russian Federation. As efficacy criteria was used proportion of limbs salvaged up to 15% of minimum statin price. Scenario C or D may be acceptable for the industry and offer government 37% or 35% extra decrease in statin expenditure. This pilot study may spotlight possible opportunities in the controlling statin market budget for government.

PCV22

A SIMPLE RISK SCORE IDENTIFIES INDIVIDUALS, IN EUROPEAN SETTINGS, MORE LIKELY TO INCUR HIGHER MEDICAL COSTS

Guda S, Alperin P, Schuetz CA
1Archimedes, Inc., San Francisco, CA, USA

OBJECTIVES: To estimate the effectiveness of using a simple risk score comprising only non-biochemical parameters to identify individuals more likely to incur